X

Trial Profile

A registrational trial of axalimogene filolisbac in combination with nivolumab for patients with PRmCC

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 26 Feb 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Axalimogene filolisbac (Primary) ; Nivolumab (Primary)
Indications Cervical cancer
Focus Registrational; Therapeutic Use
Acronyms ADVANCE
Sponsors Advaxis; Ayala Pharmaceuticals

Most Recent Events

19 Jan 2023 According to an Ayala Pharmaceuticals media release, Advaxis merged with Ayala Pharmaceuticals to form Ayala Pharmaceuticals.
16 Feb 2018 New trial record
13 Feb 2018 According to an Advaxis media release, the company is planning to initiate this trial in 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com